IDEXX Laboratories (IDXX) Financials

IDEXX Laboratories showed solid top-line and earnings growth in Q1 2026, but the balance sheet and cash flow still reflect a company that is actively returning capital to shareholders while carrying meaningful debt.

For the quarter ended March 31, 2026, revenue rose to $1.14 billion from $998.4 million in Q1 2025, while net income increased to $278.4 million from $242.7 million. Gross margin remained strong, with gross profit of $722.7 million on roughly $418.1 million of cost of revenue.

Key positives include continued revenue growth, healthy operating profitability, and strong operating cash generation. However, the company also continued heavy share repurchases and still carries a sizable debt load, which limits balance-sheet flexibility.

• Revenue growth continued. Q1 2026 revenue increased about 14% year over year, showing that demand for IDEXX’s products and services remains healthy.
• Earnings grew faster than revenue. Net income rose about 15% year over year, while diluted EPS improved to $3.47 from $2.96.
• Operating income stayed very strong. Operating income reached $362.6 million, indicating the business still converts sales into profits efficiently.
• Operating cash flow was robust. The company generated $266.2 million in operating cash in Q1 2026.
• Cash generation comfortably covered capex. Capital spending was only $32.0 million, leaving ample cash after investing needs.
• Shareholder returns remain a priority. IDEXX repurchased $351.0 million of common equity in the quarter.
• Gross margin remains high, but cost of revenue is still rising. Revenue growth was accompanied by a higher absolute cost base, so investors should watch margin trends.
• Working capital used cash in the quarter. Changes in operating assets and liabilities reduced cash flow by $75.2 million, which is not unusual but worth monitoring.
• Debt remains meaningful. Total debt was roughly $980 million at quarter-end, including $680.0 million of short-term debt and $299.9 million of long-term debt.
• Liquidity is not excessive. Cash and equivalents were only $200.5 million versus total current liabilities of $1.30 billion.

Looking at the longer trend, IDEXX has delivered a fairly consistent pattern of mid- to high-single-digit revenue growth in 2024–2025, followed by stronger acceleration in early 2026. Earnings have generally moved in the same direction, which suggests the business is still expanding rather than relying on one-time gains.

That said, the company’s balance sheet shows large treasury stock balances and a persistent reliance on debt financing alongside buybacks. Equity was $1.56 billion in Q1 2026, but total liabilities were still higher at $1.83 billion, so leverage remains an important watch item.

Bottom line: IDEXX looks financially healthy from an operating standpoint, with strong profitability and cash generation. The main risks to monitor are the company’s debt load, modest cash cushion relative to current liabilities, and ongoing aggressive buybacks.